Table 4 Baseline clinical and demographic data between RA patients with or without pneumonia

 Age (years)

68.6 ± 10.8

62.8 ± 11.9

0.010

 Gender, male/female

7 (21.9%)/25 (78.1%)

189 (21.8%)/679 (78.2%)

0.989

 Smoking history

7 (21.9%)

199 (22.9%)

0.889

 CRP (mg/dl)

1.14 ± 2.29

0.48 ± 0.97

0.023

 Serum albumin (g/dl)

3.95 ± 0.44

4.07 ± 0.37

0.210

 Serum creatinine (mg/dl)

0.70 ± 0.21

0.68 ± 0.31

0.248

 RA duration (years)

12.3 ± 8.3

11.9 ± 10.1

0.378

 HAQ

0.78 ± 0.81

0.66 ± 0.74

0.564

 DAS28 (CRP)

2.32 ± 0.97

2.48 ± 1.13

0.548

 SDAI

6.72 ± 6.11

8.41 ± 8.20

0.237

 CDAI

5.64 ± 4.76

7.94 ± 7.94

0.123

 Cardiovascular disease

13 (40.6%)

245 (28.2%)

0.128

  CVA

2 (6.3%)

22 (2.5%)

0.209

  Ischemic heart disease

1 (3.1%)

17 (2.0%)

0.482

  Hypertension

10 (31.3%)

215 (24.8%)

0.406

  Arrythmia

2 (6.3%)

9 (1.0%)

0.055

  Cardiac failure

2 (6.3%)

8 (0.9%)

0.046

 Metabolic disease

10 (31.3%)

197 (22.7%)

0.259

  Hyperlipidemia

6 (18.8%)

122 (14.1%)

0.297

  Hyperuricemia

0

9 (1.0%)

0.721

  Diabetes

5 (15.6%)

88 (10.1%)

0.229

 CKD

2 (6.3%)

33 (3.8%)

0.356

 Autoimmune disease

1 (3.1%)

36 (4.1%)

0.617

 Rheumatoid lung

14 (43.8%)

138 (15.9%)

<0.0001

  Interstitial pneumonia

11 (34.4%)

91 (10.5%)

<0.0001

  Bronchial lesion

3 (9.4%)

35 (4.0%)

0.148

  Pleural lesion

1 (3.1%)

11 (1.3%)

0.354

 COPD

0

27 (3.1%)

0.371

 NTM

1 (3.1%)

14 (1.6%)

0.422

PPSV23 vaccination

17 (53.1%)

447 (51.5%)

0.856

 PSL

18 (56.3%)

438 (50.5%)

0.520

  Dose of prednisolone (mg/day)

5.61 ± 4.90

4.58 ± 2.69

0.521

 MTX

20 (62.5%)

584 (67.3%)

0.572

 Dose of MTX (mg/week)

7.90 ± 2.38

8.18 ± 2.82

0.660

 TAC

4 (12.5%)

116 (13.4%)

0.573

 Biologics

14 (43.8%)

496 (57.1%)

0.133